lilly pharmacy tirzepatide FDA approval for Zepbound (tirzepatide) injection, the first and only obesity treatment of its kind that activates both GIP and GLP-1 hormone receptors - Eli FDA approves tirzepatide, Eli Lilly's

Explore our 29-step guide on semaglutide and tirzepatide for weight loss

Achieve your health goals now

With semaglutides (weight loss) patent expiring in January 2026, Sandoz is positioning to undercut brands like Ozempic, Zepbound and Wegovycurrently pegged at $200$400/monthby up to 70%

With advancements in weight-loss treatments, options like glucagon-like peptide-1 (GLP-1) receptor agonists and bariatric surgery are helping individuals achieve their goals.

Fueled by record demand for Ozempic, Wegovy, and Mounjaro, the companys parent, Sigma Healthcare, reported a 17% rise in sales for the first quarter of fiscal 2026

These worries are valid and deserve a clear, clinical explanation